Details

Autor(en) / Beteiligte

• Kang, Jihoon
• Hwang, Inhwan
• Yoo, Changhoon
• Kim, Kyu-pyo
• Jeong, Jae Ho
• Chang, Heung-Moon
• Lee, Sang Soo
• Park, Do Hyun
• Song, Tae Jun
• Seo, Dong Wan
• Lee, Sung Koo
• Kim, Myung-Hwan
• Hong, Seung-Mo
• Shin, Sang Hyun
• Hwang, Dae Wook
• Song, Ki Byung
• Lee, Jae Hoon
• Kim, Song Cheol
• Ryoo, Baek-Yeol

Titel

Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis

Ist Teil von

• Investigational new drugs, 2018-08, Vol.36 (4), p.732-741

Ort / Verlag

New York: Springer US

Erscheinungsjahr

2018

Quelle

MEDLINE

Beschreibungen/Notizen

• Summary Purpose nab -paclitaxel plus gemcitabine (AG) and FOLFIRINOX have been established as standard first-line treatment in metastatic pancreatic cancer (mPC). We performed retrospective analysis comparing the efficacies of AG and FOLFIRINOX in daily practice setting. Materials and Methods We analyzed 308 patients who presented initially as mPC and received AG ( n  = 149) or FOLFIRINOX ( n  = 159) as first-line treatment between 2013 and 2016. Primary endpoints were progression-free survival (PFS) and overall survival (OS). Result There were no significant differences between the two groups in terms of baseline characteristics, except older age and higher Charlson Comorbidity Index (CCI) score in AG group. The response rates (34% vs 34%) and median PFS (6.8 vs 5.1 months) were comparable between two groups ( p  = 0.88 and p  = 0.19, respectively), while median OS was significantly better with AG than FOLFIRINOX (11.4 vs 9.6 months; p  = 0.002). Elevated baseline CA19–9 level and liver metastasis were independent adverse prognostic factors for PFS and OS. In subgroup analyses, PFS with AG was better in patients with age ≥ 65 years, peritoneal metastasis, and higher CCI than that with FOLFIRINOX. Conclusion Both AG and FOLFIRINOX showed comparable efficacy outcomes in daily practice setting. AG might be preferentially considered in patients with peritoneal metastasis, comorbid medical conditions or old age.